12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema

Key Takeaways Explain This Topic AI

Stevenson/Nohria hemodynamic profiling stratifies acute heart failure into four distinct quadrants based on congestion (wet vs. dry; pulmonary capillary wedge pressure > 18 mmHg) and systemic perfusion (warm vs. cold; cardiac index < 2.2 L/min/m^2), directly dictating tailored pharmacotherapy.

Noninvasive ventilation (CPAP and BiPAP) rapidly alleviates acute cardiogenic pulmonary edema by decreasing LV transmural afterload and systemic venous preload while reducing work of breathing, with the 3CPO trial demonstrating rapid symptom and physiologic improvement without difference in 7-day mortality.

The DOSE trial established that high-dose loop diuretic strategies (2.5 times total oral daily dose given intravenously) yield superior net fluid loss and dyspnea relief compared to low-dose strategies without lasting renal injury, with equivalent efficacy observed between continuous infusion and twice-daily bolus dosing.

Sympathetic Crashing Acute Pulmonary Edema (SCAPE) represents extreme acute afterload mismatch driven by neurohormonal vasoconstriction rather than hypervolemia; emergent management demands aggressive high-dose intravenous nitroglycerin boluses and infusions coupled with immediate noninvasive ventilation.

In patients with acute decompensated heart failure and cardiorenal syndrome, the CARRESS-HF trial demonstrated that stepped pharmacologic therapy is superior to routine ultrafiltration, which increased adverse renal and vascular events without improving fluid removal or clinical outcomes.

Last updated: October 2026

Hemodynamic Profiling: The Stevenson / Nohria Classification

Acute decompensated heart failure (ADHF) is a heterogeneous syndrome characterized by the rapid onset or worsening of symptoms and signs of heart failure requiring urgent medical evaluation and intervention. Rather than treating heart failure as a uniform entity, modern critical care management relies on rapid hemodynamic phenotyping developed by Stevenson and Nohria. This bedside classification stratifies patients along two primary physiological axes:

Congestion (Wet vs. Dry) : Reflects elevated left ventricular filling pressures, clinically corresponding to a pulmonary capillary wedge pressure (PCWP) > 18 mmHg > 18\text{ mmHg} > 18 mmHg or central venous pressure (CVP) > 10 − 12 mmHg > 10-12\text{ mmHg} > 10 − 12 mmHg . Clinical markers include orthopnea, paroxysmal nocturnal dyspnea, jugular venous distention (JVD), hepatojugular reflux, pulmonary crackles, ascites, and peripheral pitting edema.

Perfusion (Warm vs. Cold) : Reflects adequacy of cardiac output and systemic tissue perfusion, clinically corresponding to a cardiac index (CI) < 2.2 L/min/m 2 < 2.2\text{ L/min/m}^2 < 2.2 L/min/m 2 . Clinical markers include narrow pulse pressure (proportional pulse pressure [ SBP − DBP ] / SBP < 25 % [\text{SBP} - \text{DBP}] / \text{SBP} < 25\% [ SBP − DBP ] / SBP < 25% ), cool clammy extremities, delayed capillary refill, mental status changes (lethargy, obtundation), prerenal azotemia with worsening renal function, and metabolic lactic acidosis.

This 2x2 matrix divides patients into four distinct hemodynamic profiles:

Profile A ("Warm and Dry") : Compensated heart failure with normal filling pressures (PCWP ≤ 18 mmHg \le 18\text{ mmHg} ≤ 18 mmHg ) and preserved tissue perfusion (CI ≥ 2.2 L/min/m 2 \ge 2.2\text{ L/min/m}^2 ≥ 2.2 L/min/m 2 ). These patients do not require acute in-hospital resuscitation; therapy focuses on optimizing oral guideline-directed medical therapy (GDMT).

Profile B ("Warm and Wet") : The most common presentation (~65% to 70% of ADHF hospitalizations). Characterized by elevated filling pressures (PCWP > 18 mmHg > 18\text{ mmHg} > 18 mmHg ) but preserved systemic perfusion (CI ≥ 2.2 L/min/m 2 \ge 2.2\text{ L/min/m}^2 ≥ 2.2 L/min/m 2 ). The primary therapeutic objective is rapid decongestion using intravenous loop diuretics combined with intravenous vasodilators (nitroglycerin or sodium nitroprusside) to reduce preload and afterload.

Profile C ("Cold and Wet") : Represents decompensated heart failure with cardiogenic hypoperfusion or true cardiogenic shock (~15% to 20% of cases). Characterized by severe congestion (PCWP > 18 mmHg > 18\text{ mmHg} > 18 mmHg ) and severely depressed cardiac output (CI < 2.2 L/min/m 2 < 2.2\text{ L/min/m}^2 < 2.2 L/min/m 2 ). Systemic vascular resistance (SVR) is markedly elevated as a compensatory response:

SVR = 80 × MAP − CVP CO \text{SVR} = 80 \times \frac{\text{MAP} - \text{CVP}}{\text{CO}} SVR = 80 × CO MAP − CVP ​

Therapy requires restoring perfusion before aggressive diuresis. Inotropic agents (dobutamine or milrinone) are indicated to augment contractility, vasopressors (norepinephrine) are added if mean arterial pressure (MAP) is < 65 mmHg < 65\text{ mmHg} < 65 mmHg , and mechanical circulatory support (MCS; e.g., intra-aortic balloon pump, Impella, or venoarterial ECMO) is initiated for refractory shock.

Profile L ("Cold and Dry") : Characterized by low perfusion (CI < 2.2 L/min/m 2 < 2.2\text{ L/min/m}^2 < 2.2 L/min/m 2 ) without congestion (PCWP ≤ 18 mmHg \le 18\text{ mmHg} ≤ 18 mmHg ). This profile represents hypovolemia or excessive diuretic therapy in a patient with chronic cardiac dysfunction. Management requires cautious, incremental volume administration (crystalloid boluses of 250 to 500 mL 250\text{ to }500\text{ mL} 250 to 500 mL ) under close hemodynamic monitoring to raise preload along the ascending limb of the Frank-Starling curve.

Hemodynamic Profile Filling Pressure (PCWP) Cardiac Perfusion (CI) Classic Clinical Manifestations Primary Management Priorities

Profile A (Warm & Dry) Normal ( ≤ 18 mmHg \le 18\text{ mmHg} ≤ 18 mmHg ) Preserved ( ≥ 2.2 L/min/m 2 \ge 2.2\text{ L/min/m}^2 ≥ 2.2 L/min/m 2 ) Euvolemic, warm extremities, clear lungs, baseline mentation Optimize oral GDMT; investigate non-cardiac causes for symptoms

Profile B (Warm & Wet) Elevated ( > 18 mmHg > 18\text{ mmHg} > 18 mmHg ) Preserved ( ≥ 2.2 L/min/m 2 \ge 2.2\text{ L/min/m}^2 ≥ 2.2 L/min/m 2 ) JVD, bibasilar crackles, orthopnea, edema, warm extremities IV loop diuretics + IV vasodilators (nitroglycerin/nitroprusside)

Profile C (Cold & Wet) Elevated ( > 18 mmHg > 18\text{ mmHg} > 18 mmHg ) Depressed ( < 2.2 L/min/m 2 < 2.2\text{ L/min/m}^2 < 2.2 L/min/m 2 ) Cool extremities, narrow pulse pressure, oliguria, high lactate, JVD Inotropes (dobutamine/milrinone) ± \pm ± vasopressors (norepinephrine) ± \pm ± MCS; diuresis once perfusion improves

Profile L (Cold & Dry) Normal/Low ( ≤ 18 mmHg \le 18\text{ mmHg} ≤ 18 mmHg ) Depressed ( < 2.2 L/min/m 2 < 2.2\text{ L/min/m}^2 < 2.2 L/min/m 2 ) Cool extremities, postural hypotension, clear lungs, rising BUN/Cr Cautious crystalloid fluid challenge ( 250 − 500 mL 250-500\text{ mL} 250 − 500 mL ); re-evaluate hemodynamics

Note

Distinguishing between Profile B and Profile C is the most critical immediate bedside determination. Administering high-dose vasodilators or aggressive loop diuretics to a patient in Profile C before addressing cardiac output precipitates profound hypotension, worsening coronary and renal ischemia, and rapid hemodynamic collapse.

Noninvasive Ventilation in Acute Cardiogenic Pulmonary Edema

Acute cardiogenic pulmonary edema (ACPE) represents a medical emergency in which rapid hydrostatic transudation of fluid into the pulmonary interstitium and alveoli leads to severe ventilation-perfusion mismatch, shunt physiology, hypoxemic respiratory failure, and markedly increased work of breathing. Noninvasive ventilation (NIV)—encompassing continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP)—is a first-line intervention that alters cardiopulmonary hemodynamics through positive intrathoracic pressure.

Cardiopulmonary Hemodynamics of Positive Intrathoracic Pressure

Positive intrathoracic pressure exerts favorable hemodynamic effects in acute left-sided heart failure:

Reduction of LV Afterload : Left ventricular afterload is determined by LV transmural systolic pressure, which is the pressure difference between the interior of the left ventricle and the surrounding pleural space:

Transmural LV Systolic Pressure = P LV − P pleural \text{Transmural LV Systolic Pressure} = P_{\text{LV}} - P_{\text{pleural}} Transmural LV Systolic Pressure = P LV ​ − P pleural ​

In spontaneous respiratory distress, vigorous inspiratory efforts generate highly negative pleural pressures (down to − 15 to − 25 cmH 2 O -15\text{ to }-25\text{ cmH}_2\text{O} − 15 to − 25 cmH 2 ​ O ), which dramatically increases transmural LV systolic wall tension and afterload. By delivering continuous positive airway pressure, NIV elevates P pleural P_{\text{pleural}} P pleural ​ , lowering transmural pressure and immediately decreasing LV afterload. This facilitates systolic emptying and enhances forward stroke volume.

2. Reduction of LV Preload : Positive intrathoracic pressure decreases the pressure gradient for systemic venous return to the right heart, reducing right and left ventricular end-diastolic volumes. In the failing, volume-overloaded ventricle operating on the plateau or descending limb of the Frank-Starling curve, this reduction in preload lowers pulmonary capillary hydrostatic pressure without compromising cardiac output.

3. Alveolar Recruitment and Gas Exchange : Continuous positive end-expiratory pressure recruits fluid-filled and atelectatic alveoli, increases functional residual capacity (FRC), shifts fluid from alveolar spaces back into the pulmonary interstitium, and improves dynamic pulmonary compliance.

4. Work of Breathing and Metabolic Unloading : In ACPE, the work of breathing can consume up to 20 % to 30 % 20\%\text{ to }30\% 20% to 30% of total cardiac output. NIV offloads the respiratory musculature, reducing whole-body oxygen consumption and redistributing limited forward cardiac output toward vital systemic organs.

The 3CPO Trial and Clinical Application

The landmark 3CPO Trial (Gray et al., NEJM 2008) evaluated 1,069 patients with acute cardiogenic pulmonary edema randomized to standard oxygen therapy, CPAP ( 10 cmH 2 O 10\text{ cmH}_2\text{O} 10 cmH 2 ​ O ), or noninvasive bilevel positive pressure ventilation (inspiratory positive airway pressure [IPAP] 8 to 20 cmH 2 O 8\text{ to }20\text{ cmH}_2\text{O} 8 to 20 cmH 2 ​ O , expiratory positive airway pressure [EPAP] 4 to 10 cmH 2 O 4\text{ to }10\text{ cmH}_2\text{O} 4 to 10 cmH 2 ​ O ). Key conclusions include:

Rapid Physiological Improvement : Both CPAP and BiPAP resulted in faster resolution of dyspnea, rapid normalization of pH and PaCO 2 \text{PaCO}_2 PaCO 2 ​ , and faster improvement in hypercapnia within the first hour compared to standard oxygen therapy ( p < 0.001 p < 0.001 p < 0.001 ).

Intubation and Mortality : The 7-day mortality (~9.5%) and 30-day mortality were not significantly different between noninvasive ventilation and standard oxygen therapy, and intubation was rare and similar in both arms (2.8% vs. 2.9%). Meta-analyses that pool smaller trials (for example, the 2019 Cochrane review) do show fewer intubations and lower hospital mortality with NIV, which is why NIV remains first-line for respiratory distress from cardiogenic pulmonary edema.

CPAP vs. BiPAP Equivalence : There was no significant difference in clinical efficacy, intubation rates, or mortality between CPAP and BiPAP. Furthermore, 3CPO refuted earlier observational concerns that BiPAP was associated with higher rates of acute myocardial infarction.

Tip

In the emergency department or ICU, begin with CPAP at 5 to 10 cmH 2 O 5\text{ to }10\text{ cmH}_2\text{O} 5 to 10 cmH 2 ​ O for pure hypoxemic cardiogenic pulmonary edema. If the patient has severe concomitant hypercapnia ( PaCO 2 > 45 − 50 mmHg \text{PaCO}_2 > 45-50\text{ mmHg} PaCO 2 ​ > 45 − 50 mmHg ), prominent respiratory acidosis ( pH < 7.30 \text{pH} < 7.30 pH < 7.30 ), or underlying chronic obstructive pulmonary disease (COPD), initiate BiPAP with an IPAP of 10 − 14 cmH 2 O 10-14\text{ cmH}_2\text{O} 10 − 14 cmH 2 ​ O and EPAP of 5 cmH 2 O 5\text{ cmH}_2\text{O} 5 cmH 2 ​ O , titrating IPAP to achieve a tidal volume of 6 − 8 mL/kg 6-8\text{ mL/kg} 6 − 8 mL/kg and unload inspiratory effort.

Loop Diuretic Therapy and the DOSE Trial

Intravenous loop diuretics (furosemide, bumetanide, torsemide) represent the cornerstone of therapy for volume-overloaded ADHF. These agents act on the luminal Na + − K + − 2 Cl − \text{Na}^+-\text{K}^+-2\text{Cl}^- Na + − K + − 2 Cl − symporter in the thick ascending limb of Henle's loop, blocking the reabsorption of sodium and chloride and producing potent natriuresis and chloruresis.

Acute Hemodynamic Effects: The Biphasic Action

Loop diuretics exert a distinct biphasic physiological response:

Early Prostaglandin-Mediated Venodilation (5 to 15 minutes) : Prior to the onset of urine output, intravenous furosemide stimulates renal and systemic prostaglandin release, causing systemic venodilation. This rapidly expands capacitance veins, reduces systemic venous return, and lowers pulmonary capillary wedge pressure within minutes of bolus injection.

Late Natriuretic Phase (30 to 60 minutes) : Natriuresis and diuresis peak at 1 to 2 hours, reducing total intravascular and interstitial fluid volume.

The DOSE Trial (Diuretic Optimization Strategies Evaluation)

Historically, clinicians debated whether continuous diuretic infusion was superior to intermittent boluses and whether high-dose regimens risked acute renal injury. The DOSE Trial (Felker et al., NEJM 2011) enrolled 308 patients with acute decompensated heart failure in a 2x2 factorial randomized design comparing:

High-Dose vs. Low-Dose : High dose was defined as 2.5 times 2.5\text{ times} 2.5 times the previous total daily oral loop diuretic dose administered intravenously (e.g., if taking furosemide 80 mg 80\text{ mg} 80 mg PO daily, the patient received 200 mg 200\text{ mg} 200 mg IV daily). Low dose was defined as 1.0 times 1.0\text{ times} 1.0 times the oral home dose intravenously.

Continuous Infusion vs. Intermittent Bolus : Continuous IV infusion vs. IV boluses administered every 12 hours.

Key findings of the DOSE trial established the modern standard of care:

Continuous vs. Bolus : There was no statistically significant difference between continuous infusion and intermittent bolus dosing in terms of patient-reported global symptom relief or change in serum creatinine at 72 hours.

High-Dose vs. Low-Dose : The high-dose strategy demonstrated favorable secondary endpoints: greater net fluid loss, greater weight loss, and more rapid dyspnea relief compared to the low-dose strategy.

Renal Safety : Although the high-dose group experienced a higher incidence of transient worsening renal function ( > 0.3 mg/dL > 0.3\text{ mg/dL} > 0.3 mg/dL rise in serum creatinine at 72 hours; 23 % 23\% 23% vs. 14 % 14\% 14% ), this bump was transient, and renal function at 60 days was identical between groups. Long-term adverse events, rehospitalizations, and mortality were not increased in the high-dose cohort.

Urine Sodium and Natriuretic Response Monitoring

Current clinical guidelines emphasize assessing diuretic response early. A spot urine sodium concentration should be measured at 2 hours following diuretic administration:

Adequate Natriuresis : Urine sodium > 50 − 70 mEq/L > 50-70\text{ mEq/L} > 50 − 70 mEq/L or urine output > 100 − 150 mL/hr > 100-150\text{ mL/hr} > 100 − 150 mL/hr over the first 6 hours. Continue current diuretic regimen.

Diuretic Resistance : Urine sodium < 50 mEq/L < 50\text{ mEq/L} < 50 mEq/L or urine output < 100 mL/hr < 100\text{ mL/hr} < 100 mL/hr . Immediately double the intravenous loop diuretic dose (up to ceiling doses: furosemide 160 − 200 mg 160-200\text{ mg} 160 − 200 mg IV bolus). If resistance persists, initiate sequential nephron blockade by adding a thiazide-like diuretic (e.g., oral metolazone 2.5 − 5 mg 2.5-5\text{ mg} 2.5 − 5 mg daily or IV chlorothiazide 500 mg 500\text{ mg} 500 mg BID) or intravenous acetazolamide ( 500 mg 500\text{ mg} 500 mg daily, as supported by the ADVOR trial) to inhibit proximal tubular sodium reabsorption.

Vasodilator Therapy and the SCAPE Emergency Protocol

Intravenous vasodilators play an indispensable role in patients with acute hypertensive heart failure and normal or elevated systemic vascular resistance.

Pathophysiology of SCAPE (Sympathetic Crashing Acute Pulmonary Edema)

Sympathetic Crashing Acute Pulmonary Edema (SCAPE) represents the most extreme, hyperacute presentation of acute heart failure. Unlike chronic gradual volume accumulation over weeks, SCAPE is characterized by:

Abrupt sympathetic surge triggering massive systemic vasoconstriction.

Marked elevation of systolic blood pressure (frequently > 180 − 200 mmHg > 180-200\text{ mmHg} > 180 − 200 mmHg ) and severe afterload mismatch.

Acute central redistribution of blood from the splanchnic and venous capacitance reservoirs into the pulmonary circulation.

Alveolar flooding developing over minutes to hours ("flash pulmonary edema").

Intravascular Euvolemia : Patients in SCAPE are often not total-body hypervolemic; their primary pathology is fluid maldistribution due to afterload overload.

Warning

Treating SCAPE primarily with high-dose loop diuretics is ineffective and potentially harmful. Because these patients have fluid redistribution rather than massive fluid excess, high-dose diuretics promote intravascular volume contraction, activate the renin-angiotensin-aldosterone axis, and worsen neurohumoral vasoconstriction. The primary therapy is rapid, aggressive afterload reduction.

High-Dose Nitroglycerin SCAPE Protocol

Nitroglycerin acts predominantly as a venodilator at lower doses ( < 100 mcg/min < 100\text{ mcg/min} < 100 mcg/min ), expanding systemic venous capacitance and lowering LV preload. At high doses ( > 100 − 200 mcg/min > 100-200\text{ mcg/min} > 100 − 200 mcg/min ), it acts as a potent arterial vasodilator, reducing systemic vascular resistance, decreasing LV afterload, and breaking the vicious cycle of afterload mismatch:

Simultaneous Noninvasive Ventilation : Apply CPAP at 8 − 10 cmH 2 O 8-10\text{ cmH}_2\text{O} 8 − 10 cmH 2 ​ O or BiPAP immediately to support alveolar recruitment and lower LV transmural wall stress.

High-Dose Nitroglycerin Bolus : Administer an initial intravenous bolus of 400 to 1 , 000 mcg 400\text{ to }1,000\text{ mcg} 400 to 1 , 000 mcg over 1 to 2 minutes (or administer repeated sublingual nitroglycerin 400 mcg 400\text{ mcg} 400 mcg tablets/sprays every 2 minutes while IV access is established).

Aggressive Continuous Infusion : Start the IV infusion at 100 to 200 mcg/min 100\text{ to }200\text{ mcg/min} 100 to 200 mcg/min , rapidly titrating upward by 50 to 100 mcg/min 50\text{ to }100\text{ mcg/min} 50 to 100 mcg/min every 3 to 5 minutes based on blood pressure response (maximum doses up to 400 mcg/min 400\text{ mcg/min} 400 mcg/min ) until SBP is reduced by 20 % to 30 % 20\%\text{ to }30\% 20% to 30% or reaches < 140 − 150 mmHg < 140-150\text{ mmHg} < 140 − 150 mmHg .

Deferred Diuretic Administration : Administer low-to-moderate dose intravenous furosemide ( 20 − 40 mg 20-40\text{ mg} 20 − 40 mg ) only after blood pressure and pulmonary edema have improved under vasodilator control.

Sodium Nitroprusside: Balanced Dilation and Toxicity

Sodium nitroprusside is a direct, balanced arterial and venous vasodilator with an immediate onset and short duration of action ( 1 − 2 minutes 1-2\text{ minutes} 1 − 2 minutes ). By releasing nitric oxide non-enzymatically in vascular smooth muscle, it dramatically reduces both preload (PCWP) and afterload (SVR), making it an exceptional agent for severe hypertensive heart failure, acute aortic regurgitation, and acute mitral regurgitation.

However, sodium nitroprusside carries substantial metabolic risks:

Cyanide and Thiocyanate Toxicity : Each molecule of sodium nitroprusside contains five cyanide groups. In the bloodstream, nitroprusside reacts with hemoglobin to release free cyanide ions. Hepatic rhodanese converts cyanide to thiocyanate using sulfur donors (thiosulfate), and thiocyanate is excreted renally with a half-life of 3 to 7 days.

Risk Factors : Infusion rates > 2 − 3 mcg/kg/min > 2-3\text{ mcg/kg/min} > 2 − 3 mcg/kg/min , duration > 48 hours > 48\text{ hours} > 48 hours , pre-existing hepatic impairment (impairs conversion of cyanide to thiocyanate), or renal failure (impairs thiocyanate excretion).

Clinical Manifestations :

Cyanide Poisoning : Inhibits cytochrome c oxidase in the mitochondrial electron transport chain, blocking oxidative phosphorylation. Presents as profound, refractory lactic acidosis, mental status deterioration, and an abnormally elevated mixed venous oxygen saturation ( S v O 2 > 85 − 90 % S_v\text{O}_2 > 85-90\% S v ​ O 2 ​ > 85 − 90% ) due to inability of tissues to extract oxygen.

Thiocyanate Poisoning : Manifests as central nervous system toxicity, including delirium, confusion, tremor, hyperreflexia, tinnitus, hallucination, and seizures.

Treatment : Discontinue nitroprusside immediately. For cyanide toxicity, administer hydroxocobalamin ( 5 g 5\text{ g} 5 g IV over 15 minutes), which binds cyanide to form non-toxic cyanocobalamin (vitamin B 12 \text{B}_{12} B 12 ​ ) excreted in urine. Alternatively, administer sodium thiosulfate ( 12.5 g 12.5\text{ g} 12.5 g IV) to provide sulfur substrates for hepatic clearance.

Ultrafiltration in Decompensated Heart Failure: The CARRESS-HF Trial

Extracorporeal ultrafiltration (UF) mechanically removes plasma water across a semipermeable membrane via convective hydrostatic pressure, allowing precise control of fluid removal rates without neurohormonal activation or electrolyte derangements associated with loop diuretics.

The CARRESS-HF Trial (Cardiorenal Rescue Study in ADHF)

The CARRESS-HF Trial (Bart et al., NEJM 2012) tested whether ultrafiltration was superior to stepped pharmacologic therapy in patients with ADHF complicated by persistent congestion and worsening renal function (cardiorenal syndrome). Patients were randomized to:

Stepped Pharmacologic Therapy : Algorithm-driven diuretic titration, sequential nephron blockade with metolazone, and intravenous vasodilators or inotropes targeted to maintain urine output > 3 − 5 L/day > 3-5\text{ L/day} > 3 − 5 L/day .

Ultrafiltration : Fixed ultrafiltration rate of 200 mL/hr 200\text{ mL/hr} 200 mL/hr adjusted only for hemodynamic instability.

Trial Outcomes and Clinical Implications

Renal Function : At 96 hours, patients in the ultrafiltration group experienced a significantly greater increase in serum creatinine ( + 0.23 mg/dL +0.23\text{ mg/dL} + 0.23 mg/dL vs. − 0.04 mg/dL -0.04\text{ mg/dL} − 0.04 mg/dL in the pharmacologic arm, p = 0.003 p = 0.003 p = 0.003 ).

Fluid and Weight Loss : Weight loss at 96 hours was virtually identical between the two arms (~ 5.7 kg 5.7\text{ kg} 5.7 kg vs. ~ 5.5 kg 5.5\text{ kg} 5.5 kg , p = 0.58 p = 0.58 p = 0.58 ).

Adverse Events : The ultrafiltration group experienced significantly higher rates of serious adverse events ( 72 % 72\% 72% vs. 57 % 57\% 57% , p = 0.03 p = 0.03 p = 0.03 ), including catheter-related bacteremia, circuit thrombosis, hemorrhage, and access-site vascular complications.

Conclusion : Routine ultrafiltration is inferior to stepped pharmacologic therapy for patients with acute decompensated heart failure and worsening renal function. Ultrafiltration is strictly reserved as salvage therapy for refractory volume overload unresponsive to maximized sequential diuretic regimens and inotropic therapy.